1. Generics Bulletin
  2. >>Preview

What’s Next? Five Things To Look Out For In February

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for February 2025.

What's Next Image
Source: Norstella

The floodgates are due to open for US biosimilar competition to Stelara (ustekinumab) in February, with a multitude of ustekinumab biosimilars that have received US Food and Drug Administration approval set to launch under the terms of patent-litigation settlement agreements.

Partners Alvotech and Teva – which gained approval for their Selarsdi (ustekinumab-aekn) version in April –...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Preview

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

What’s Next? Five Things To Look Out For In April

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for April 2025.

What’s Next? Five Things To Look Out For In March

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for March 2025.

What’s Next? Five Things To Look Out For In February

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for February 2025.

More from Biosimilars

Hikma Teams With Mark Cuban’s Cost Plus For US Ustekinumab Launch

 
• By Dave Wallace

Hikma has set out expectations for its nascent biosimilars business in the US, after launching its Bio-Thera-partnered Starjezma rival to Stelara through Mark Cuban’s Cost Plus Drug Company. Meanwhile, a trading update issued by the firm has pointed to a slight decline in Injectables margins.

FDA’s Streamlined Biosimilar Rules Seen As ‘Less Burdensome’ Step Forward, Says Fresenius

 
• By Dean Rudge

Fresenius has acknowledged that the FDA’s draft guidance could shorten approval timelines and cut trial costs for biosimilars, even though it “may have not fundamentally changed the existing framework.”

Alvotech Grabs UK Approval For Simponi Biosimilar After FDA Knockback

 
• By Urtė Fultinavičiūtė

Alvotech forges ahead with its golimumab biosimilar after receiving approval in the UK, as the US market will have to wait.